Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Contact
Bahnhofstrasse 20
Zug6300
CHET: +41 417119325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
49
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.80 | 66.60 | -0.72% |
| CAC 40 | 8,304.15 | 9.09 | -0.11% |
| DAX 40 | 24,895.64 | 42.95 | 0.17% |
| Dow JONES (US) | 49,525.25 | 73.27 | 0.15% |
| FTSE 100 | 10,441.64 | 39.20 | 0.38% |
| HKSE | 26,567.12 | 465.42 | -1.72% |
| NASDAQ | 22,592.65 | 4.50 | -0.02% |
| Nikkei 225 | 56,941.97 | 697.87 | -1.21% |
| NZX 50 Index | 13,198.18 | 309.10 | -2.29% |
| S&P 500 | 6,846.66 | 13.90 | 0.20% |
| S&P/ASX 200 | 8,917.60 | 55.30 | -0.62% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |